PolyPid (PYPD) Income from Continuing Operations (2019 - 2026)
PolyPid (PYPD) posted Income from Continuing Operations of 7728000.0 for Q1 2026, down 10.5% sequentially from 8635000.0 in Q4 2025, and down 6.28% YoY from 8246000.0 in Q1 2025.
PolyPid (PYPD) Income from Continuing Operations (2019 - 2026) Analysis & Trends
PolyPid has reported Income from Continuing Operations for 8 years, with the latest figure at 7728000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 6.28% year-over-year to 7728000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 33641000.0 (up 9.4% YoY) and the FY2025 annual result came in at 34169000.0, down 17.73% from the prior year.
- Income from Continuing Operations declined to 7728000.0 in Q1 2026 per PYPD's latest filing, from 8635000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 11874000.0 in Q1 2022 and troughed at 5554000.0 in Q3 2023.
- A 5-year average of 7873588.24 and a median of 7720000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 265.25% in 2022, down 52.18% in 2022.
- Over 5 years, Income from Continuing Operations stood at 6457000.0 in 2022, then decreased by 1.84% to 6338000.0 in 2023, then surged by 34.02% to 8494000.0 in 2024, then climbed by 1.66% to 8635000.0 in 2025, then retreated by 10.5% to 7728000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 7728000.0, 8635000.0, and 7407000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | PolyPid | 113.86 Mn | 107.09 Mn | - | 7.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23.30 Mn |
| Mar 31, 2026 | 7.73 Mn |
| Dec 31, 2025 | 8.64 Mn |
| Sep 30, 2025 | 7.41 Mn |
| Jun 30, 2025 | 9.87 Mn |
| Mar 31, 2025 | 8.25 Mn |
| Dec 31, 2024 | 8.49 Mn |
| Sep 30, 2024 | 7.72 Mn |
| Jun 30, 2024 | 6.29 Mn |
| Mar 31, 2024 | 6.43 Mn |
| Dec 31, 2023 | 6.34 Mn |
| Sep 30, 2023 | 5.55 Mn |
| Jun 30, 2023 | 5.82 Mn |
| Mar 31, 2023 | 6.02 Mn |
| Dec 31, 2022 | 6.46 Mn |
| Sep 30, 2022 | 9.12 Mn |
| Jun 30, 2022 | 11.85 Mn |
| Mar 31, 2022 | 11.87 Mn |
| Dec 31, 2021 | 13.50 Mn |
| Sep 30, 2021 | 9.94 Mn |